CytoDyn announced encouraging clinical findings from a compassionate use study of leronlimab in patients with advanced metastatic colorectal cancer (mCRC). Three out of five patients treated with leronlimab experienced at least a partial response, with one patient achieving a complete response and remaining alive five years post-treatment. These findings will be presented by Dr. Benjamin Weinberg at the ESMO Gastrointestinal Cancers Congress 2025 in Barcelona.
These results are particularly important because they suggest leronlimab’s potential efficacy in treating mCRC, a challenging cancer with limited treatment options. The complete response observed in one patient is especially noteworthy, highlighting the possibility of long-term survival benefits. This data reinforces the rationale behind CytoDyn’s ongoing Phase II trial for relapsed/refractory microsatellite stable CRC, which is currently enrolling patients. The positive compassionate use data could potentially accelerate enrollment and investor interest in the ongoing trial.
The compassionate use study indicated a favorable safety profile for leronlimab, consistent with previous studies. This is crucial for any new cancer treatment, as minimizing side effects is essential for patient well-being. CytoDyn believes leronlimab may also have broader applications in treating various solid tumor types if these positive mCRC results are confirmed in larger, prospective studies. Additionally, research suggests leronlimab could act as a “priming” agent for cancer patients with low PD-L1 levels, potentially expanding its therapeutic utility in combination with checkpoint inhibitors.
This early data generates optimism about leronlimab’s potential role in treating mCRC and possibly other solid tumors. The upcoming Phase II trial results will be critical in validating these findings and determining the next steps for leronlimab’s development in oncology. Positive results could significantly impact the treatment landscape for mCRC and potentially position leronlimab as a valuable new therapeutic option. Further research exploring leronlimab’s potential as a priming agent could also unlock new avenues for combination therapies, particularly in patients who haven’t responded to existing treatments.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
